Rezdiffra held a clean first-mover year; Wegovy’s August 2025 approval turns a monopoly into a two-drug access fight.
Two agents are approved for noncirrhotic MASH with F2–F3 fibrosis in the United States, across two mechanism classes. Resmetirom (Rezdiffra, Madrigal) is a liver-directed THR-β agonist that launched in April 2024 with a fibrosis-improvement label. Semaglutide 2.4 mg (Wegovy, Novo Nordisk) added a systemic-metabolic option on 15 August 2025, backed by an established cardiometabolic story and a broad prescriber base.
The commercial question has shifted. With both agents covered, payers are building two-drug formularies rather than gatekeeping a single entrant, so the battleground moves from initial approval to Year 0 to Year 1 persistence. This report gives commercial and market-access teams the verified competitive map to defend preferred access before guideline-preferred positioning hardens.
Sample exhibit: the US MASH competitive set, head to head
| Agent | Mechanism | Company | Fibrosis response | Access posture |
|---|---|---|---|---|
| Rezdiffra (resmetirom) | THR-β agonist, oral | Madrigal | ~26%* | First-mover, specialty-hepatology anchored |
| Wegovy (semaglutide 2.4mg) | GLP-1 RA, injectable | Novo Nordisk | ~37%* | Metabolic halo, broad prescriber base |
*Fibrosis-improvement rates from separate pivotal trials, not a head-to-head comparison. Sources: FDA labels; MAESTRO-NASH; ESSENCE. Illustrative for this demo page.
Sources: MASH resolution and fibrosis-improvement figures: MAESTRO-NASH, Harrison et al., N Engl J Med 2024, PMID 38324483 (DOI 10.1056/NEJMoa2309000); ESSENCE, N Engl J Med, PMID 40305708 (DOI 10.1056/NEJMoa2413258). Figures are from separate trials and are not head-to-head. Approvals: Rezdiffra NDA217785, Drugs@FDA; Wegovy-MASH accelerated approval Aug 15, 2025, Novo Nordisk / PRNewswire. Trials: NCT03900429, NCT04822181, NCT04849728, NCT06215716, NCT06528314, NCT06318169, NCT06419374 (ClinicalTrials.gov).
The questions your commercial and market-access leaders are asking about US MASH
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The verified regulatory timeline: Rezdiffra approved Mar 14, 2024
- Wegovy-MASH approved Aug 15, 2025. Both hold accelerated (Subpart H) approval for the same noncirrhotic F2-F3 label. The brief reframes your planning from pre-entry defense to Year 0-1 retention
Delivers
- Side-by-side MAESTRO-NASH vs ESSENCE endpoint read (cross-trial, not head-to-head). Semaglutide leads on resolution (62.9% vs 34.3% placebo in ESSENCE) and weight (-10.5%)
- Rezdiffra's defensible angles are its direct fibrosis-targeted MOA, oral convenience, and being the only agent with an ongoing histology-plus-clinical-outcome confirmatory readout
Delivers
- The US payer architecture map (commercial, Medicare Part D, Medicaid, PBM intermediation) and the prior-authorization / step-edit / formulary-exclusion levers payers already aim at GLP-1s. The play: preferred tier plus first-line PA tied to FIB-4 / elastography-confirmed F2-F3
Delivers
- The small-molecule vs biologic asymmetry: resmetirom is eligible for Medicare Drug Price Negotiation selection years earlier than a biologic-class GLP-1. Implication for net-price strategy and the case to monetize and entrench access now
Delivers
- Pipeline read: lanifibranor (Inventiva, pan-PPAR, NATiV3, topline H2 2026-2027) and the FGF21 class (efruxifermin / Akero, pegozafermin / 89bio) — including the compensated-cirrhosis segment that neither Rezdiffra nor Wegovy currently covers
Delivers
- The US-specific funnel: 6.7M F2-F3-eligible adults, most undiagnosed or unstaged in primary care. Conversion depends on FIB-4 reflex to elastography/MRI in PCP, endocrine and hepatology pathways — a CI lever independent of the THR-β vs GLP-1 efficacy debate
Need a question that isn't here?
Scope a custom brief with usWhat's inside
- Rezdiffra (resmetirom) approval Mar 14, 2024 — NDA217785
- Wegovy (semaglutide 2.4 mg) approval Aug 15, 2025
- Both on accelerated (Subpart H) approval; cirrhosis excluded
- MAESTRO-NASH resolution & fibrosis endpoints (PMID 38324483)
- ESSENCE resolution, fibrosis & weight endpoints (PMID 40305708)
- Where Rezdiffra holds a defensible argument vs semaglutide
- Commercial · Medicare Part D · Medicaid · PBM intermediation
- GLP-1 utilization-management crosshairs (PA, step edits)
- Preferred-tier + first-line PA play tied to FIB-4/elastography
- Small-molecule vs biologic negotiation horizon
- Part D negotiated prices from 2026; $2,000 OOP cap from 2025
- Implications for net-price and entrenchment strategy
- Lanifibranor / NATiV3 (Inventiva, pan-PPAR)
- FGF21 class: efruxifermin (Akero), pegozafermin (89bio)
- Compensated-cirrhosis segment neither incumbent covers
- 6.7M F2-F3 label-eligible pool — diagnosed fraction
- FIB-4 reflex to elastography/MRI referral pathway
- Owning the diagnose-and-stage pathway as a share lever
Included with every brief
Every figure on this page is sourced and verifiable
Prepared by MoatRx analysts.
This brief is built on regulatory filings (Drugs@FDA, openFDA), peer-reviewed Phase 3 trials (New England Journal of Medicine), trial registrations (ClinicalTrials.gov), a published US burden model (JAMA Network Open), and company financial disclosures. The central correction (that semaglutide is already an in-market US MASH competitor, not a future ~2027 entrant) was confirmed against the FDA-approval record before this page was written.
AXLRx applies a verify-or-drop standard: a figure is only presented if it carries a resolvable identifier (NDA number, PMID, NCT, or filing) and clears independent verification. Numbers without a source do not appear.
- Rezdiffra (resmetirom) — FDA accelerated approval Mar 14, 2024 for noncirrhotic NASH with F2-F3 fibrosis; NDA217785 (Drugs@FDA). Weight-based dosing 80mg <100kg / 100mg ≥100kg; avoid in decompensated cirrhosis (REZDIFFRA US Prescribing Information, openFDA).
- Wegovy (semaglutide 2.4 mg) — FDA accelerated approval Aug 15, 2025 for noncirrhotic MASH with F2-F3 fibrosis (Novo Nordisk / PRNewswire); MASH indication confirmed on the current FDA label (openFDA). Confirms the duopoly is already live, not a 2027 entry.
- MAESTRO-NASH — resmetirom MASH resolution 25.9%/29.9% (80/100mg) vs 9.7% placebo; ≥1-stage fibrosis improvement 24.2%/25.9% vs 14.2% (Harrison et al., NEJM 2024, PMID 38324483; NCT03900429).
- ESSENCE — semaglutide MASH resolution 62.9% vs 34.3%; fibrosis improvement 36.8% vs 22.4%; mean weight change -10.5% vs -2.0% (NEJM, PMID 40305708; NCT04822181). Cross-trial with MAESTRO-NASH, not a head-to-head comparison.
- US burden — MASLD 86.3M adults (33.7%, 2020); MASH 14.9M (5.8%); MASH + ≥F2 fibrosis (label-eligible) 6.7M rising to 11.7M by 2050 (JAMA Network Open, PMID 39821400).
- IRA Medicare Drug Price Negotiation — small molecules (resmetirom) face an earlier negotiation horizon (~9 years post-approval) than biologics (~13 years); Part D negotiated prices from 2026; Part D $2,000 OOP cap from 2025 (KFF).
- Madrigal Q1 2026 — Rezdiffra net revenue $311.3M, +127% YoY, 42,250+ patients on therapy as of Mar 31, 2026 (Madrigal Pharmaceuticals SEC 8-K, CIK 1157601).
- Pipeline: lanifibranor/NATiV3 (NCT04849728, topline H2 2026-2027); efruxifermin (NCT06215716, NCT06528314); pegozafermin (NCT06318169, NCT06419374) — FGF21 class chasing compensated-cirrhosis white space (ClinicalTrials.gov).
Frequently asked questions
Commission the US MASH competitive intelligence brief for your team
If your team is defending Rezdiffra's access position against an in-market GLP-1, or modeling entry into the US MASH duopoly, this brief gives your commercial strategy and market-access leaders a verified competitive map and a defensible-moat playbook scoped to the Year 0-1 retention reality. We build it on your timeline, with every figure sourced.
A 20-minute call to confirm your decision question (access defense, entry sizing, or pipeline watch) and the geography and stage in focus.
We assemble the verified competitive map: corrected status, head-to-head clinical read, payer-defense thesis, IRA clock and pipeline — every figure source-tied.
You receive the PDF brief, the Excel competitive and funnel model, and the PowerPoint payer-defense deck — ready for your market-access director and your board.